Latest Headlines

  1. Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Sasineprocel (ANPD001) To Treat Parkinson's Disease 7/30/2026

    Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson's Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA).

  2. Sail Biomedicines Announces Strategic Collaboration To Develop New Class Of Medicines For In Vivo CAR-T 7/29/2026

    Sail Biomedicines, a Flagship Pioneering company creating a new class of RNA medicines, today announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies that have the potential to improve patient outcomes for immune-mediated diseases.

  3. Ono Pharmaceutical Partners With Phylo To Embed Agentic AI With Every Discovery Scientist 7/28/2026

    Ono Pharmaceutical Co., Ltd. (TYO: 4528, "Ono") and Phylo, Inc. ("Phylo") today announced a collaboration that brings Biomni Lab, Phylo's agentic AI platform for biomedical research, to Ono's drug discovery scientists.

  4. Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate For Drug Discovery Campaign 7/28/2026

    Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has narrowed its focus from the broader pool of SLC transport protein candidates previously identified through its structural analysis efforts, selecting a candidate for a drug discovery campaign.

  5. HAYA Therapeutics Receives FDA Fast Track Designation For HTX-001 7/28/2026

    HAYA Therapeutics SA, a clinical-stage biotechnology company pioneering precision RNA-guided therapeutics that target the regulatory genome to reprogram disease-driving cell states in common, chronic and age-related diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).

  6. Enveric Biosciences Welcomes Final FDA Guidance For Psychedelic Drug Development 7/28/2026

    Enveric Biosciences (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.

  7. Insilico Medicine Receives FDA Fast Track Designation For ISM6331, The AI-driven Pan-TEAD Inhibitor, In Advanced Mesothelioma 7/28/2026

    Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico’s proprietary AI, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment of adult patients with unresectable malignant pleural mesothelioma whose disease has progressed on or after prior treatment with anti-PD-1 antibody therapy, with or without anti-CTLA-4 antibody therapy, and platinum-based chemotherapy.

  8. Dasher Neuroscience Completes Patient Enrollment In Phase 2 Global Clinical Trial Of Lead AI Drug Candidate YA-101 For Multiple System Atrophy (MSA) 7/28/2026

    Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial evaluating YA-101, its flagship candidate for the treatment of Multiple System Atrophy (MSA).

  9. CORE Biomedicine Signs Exclusive Licensing Agreement With Eisai For Precision Oncology Programs 7/28/2026

    CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to develop and commercialize multiple preclinical oncology programs.

  10. AbelZeta Receives FDA Clearance Of Registrational Phase II Trial For C-CAR168 In Refractory Lupus Nephritis 7/27/2026

    AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the Company received the U.S. Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced Therapy (RMAT) designation regarding the multiple-center registrational Phase II clinical trial for C-CAR168, an anti-CD20/BCMA bispecific CAR-T, in the treatment of patients with Lupus Nephritis (LN) refractory to standard therapy.